Aspire Biopharma Holdings Inc (ASBP) Return on Equity ROE from the second quarter 2026 to second quarter 2025 and annually, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Aspire Biopharma Holdings Inc   (NASDAQ: ASBP)

Aspire Biopharma Holdings Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Aspire Biopharma Holdings Inc in the second quarter 2026?
Due to the lack of equity, it was not possible to calculate Aspire Biopharma Holdings Inc 's return on equity (ROE) in its second quarter 2026

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Equity Change - - - - -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -11 -12 -24 -20 -18
Return On Equity (TTM) - - - - -
ASBP's Total Ranking # # # # #
Equity (TTM) in Millions 12 4 -6 -11 -10
Seq. Equity Change 203.94 % - - - -
Seq. Net Income Change - - - - -

Back to ASBP Management Effectiveness >> ASBP's 5 Years Annual ROE >> Compare ASBP ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry #
Sector #
Overall #

Return On Equity Statistics
High Average Low
0 %
0 %
0 %
 





ASBP Annual Return On Equity (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022
Total Equity in Millions -6 -16 0 -10 0
Y / Y Equity Change - - - - -
Net Income in Millions -24 -13 4 3 0
Y / Y Net Income Change - - 33.65 % - -
Return On Equity - - - - -

Back to ASBP Management Effectiveness >> ASBP's 5 Years Annual ROE >> Compare ASBP ROE to its Competitors




Annual Roe Comment
Despite deterioration in net income, company improved ROE to in 2025, company improved ROE to 33.65 % compared to the prior year.


More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
ASBP's' Return on Equity at Yahoo Finance
ASBP's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for ASBP's Competitors
Subscribers only: Roe for Aspire Biopharma Holdings Inc 's Suppliers
Subscribers only: Return On Equity for ASBP's Customers




Companies with similar Return On Equity at Jun 30 2026, within Healthcare Sector ROE
Glucotrack Inc   1,114.03 %
Elutia Inc   940.81 %

Date modified: 2026-09-02T19:46:20+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.